193 related articles for article (PubMed ID: 23955461)
1. Significant variation of immunohistochemical marker expression in paired primary and metastatic clear cell renal cell carcinomas.
Pan Z; Grizzle W; Hameed O
Am J Clin Pathol; 2013 Sep; 140(3):410-8. PubMed ID: 23955461
[TBL] [Abstract][Full Text] [Related]
2. [Expression of carbonic anhydrase IX, PAX2 and PAX8 and their association with clinicopathologic characteristics in renal epithelial tumors].
Zhang W; Yu WJ; Xia Y; Liu Y; Liu XL; Zhuang J; Li YJ
Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):442-5. PubMed ID: 24246861
[TBL] [Abstract][Full Text] [Related]
3. PAX2 and PAX8 expression in primary and metastatic renal tumors: a comprehensive comparison.
Ozcan A; de la Roza G; Ro JY; Shen SS; Truong LD
Arch Pathol Lab Med; 2012 Dec; 136(12):1541-51. PubMed ID: 23194047
[TBL] [Abstract][Full Text] [Related]
4. Sporadic renal hemangioblastoma with CA9, PAX2 and PAX8 expression: diagnostic pitfall in the differential diagnosis from clear cell renal cell carcinoma.
Kuroda N; Agatsuma Y; Tamura M; Martinek P; Hes O; Michal M
Int J Clin Exp Pathol; 2015; 8(2):2131-8. PubMed ID: 25973115
[TBL] [Abstract][Full Text] [Related]
5. Value of PAX8, PAX2, napsin A, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma.
Ordóñez NG
Mod Pathol; 2013 Aug; 26(8):1132-43. PubMed ID: 23503645
[TBL] [Abstract][Full Text] [Related]
6. p63, CK7, PAX8 and INI-1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system.
Carvalho JC; Thomas DG; McHugh JB; Shah RB; Kunju LP
Histopathology; 2012 Mar; 60(4):597-608. PubMed ID: 22260386
[TBL] [Abstract][Full Text] [Related]
7. PAX2 and PAX8: useful markers for metastatic effusions.
Waters L; Crumley S; Truong L; Mody D; Coffey D
Acta Cytol; 2014; 58(1):60-6. PubMed ID: 24334997
[TBL] [Abstract][Full Text] [Related]
8. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
Bui MH; Seligson D; Han KR; Pantuck AJ; Dorey FJ; Huang Y; Horvath S; Leibovich BC; Chopra S; Liao SY; Stanbridge E; Lerman MI; Palotie A; Figlin RA; Belldegrun AS
Clin Cancer Res; 2003 Feb; 9(2):802-11. PubMed ID: 12576453
[TBL] [Abstract][Full Text] [Related]
9. PAX2(-)/PAX8(-)/inhibin A(+) immunoprofile in hemangioblastoma: A helpful combination in the differential diagnosis with metastatic clear cell renal cell carcinoma to the central nervous system.
Carney EM; Banerjee P; Ellis CL; Albadine R; Sharma R; Chaux AM; Burger PC; Netto GJ
Am J Surg Pathol; 2011 Feb; 35(2):262-7. PubMed ID: 21263247
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical distinction of renal cell carcinoma from other carcinomas with clear-cell histomorphology: utility of CD10 and CA-125 in addition to PAX-2, PAX-8, RCCma, and adipophilin.
Mentrikoski MJ; Wendroth SM; Wick MR
Appl Immunohistochem Mol Morphol; 2014 Oct; 22(9):635-41. PubMed ID: 25279712
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms.
Gupta R; Balzer B; Picken M; Osunkoya AO; Shet T; Alsabeh R; Luthringer D; Paner GP; Amin MB
Am J Surg Pathol; 2009 Feb; 33(2):241-7. PubMed ID: 18941400
[TBL] [Abstract][Full Text] [Related]
12. Multilocular cystic renal cell carcinoma: similarities and differences in immunoprofile compared with clear cell renal cell carcinoma.
Williamson SR; Halat S; Eble JN; Grignon DJ; Lopez-Beltran A; Montironi R; Tan PH; Wang M; Zhang S; Maclennan GT; Baldridge LA; Cheng L
Am J Surg Pathol; 2012 Oct; 36(10):1425-33. PubMed ID: 22982885
[TBL] [Abstract][Full Text] [Related]
13. Role of carbonic anhydrase IX, α-methylacyl coenzyme a racemase, cytokeratin 7, and galectin-3 in the evaluation of renal neoplasms: a tissue microarray immunohistochemical study.
Bing Z; Lal P; Lu S; Ziober A; Tomaszewski JE
Ann Diagn Pathol; 2013 Feb; 17(1):58-62. PubMed ID: 22898056
[TBL] [Abstract][Full Text] [Related]
14. PAX-2 is a helpful marker for diagnosing metastatic renal cell carcinoma: comparison with the renal cell carcinoma marker antigen and kidney-specific cadherin.
Ozcan A; Zhai Q; Javed R; Shen SS; Coffey D; Krishnan B; Truong LD
Arch Pathol Lab Med; 2010 Aug; 134(8):1121-9. PubMed ID: 20670131
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic use of PAX8, CAIX, TTF-1, and TGB in metastatic renal cell carcinoma of the thyroid.
Cimino-Mathews A; Sharma R; Netto GJ
Am J Surg Pathol; 2011 May; 35(5):757-61. PubMed ID: 21451364
[TBL] [Abstract][Full Text] [Related]
16. Utility of PAX8 and PAX2 immunohistochemistry in the identification of renal cell carcinoma in diagnostic cytology.
Knoepp SM; Kunju LP; Roh MH
Diagn Cytopathol; 2012 Aug; 40(8):667-72. PubMed ID: 22807381
[TBL] [Abstract][Full Text] [Related]
17. Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade.
Genega EM; Ghebremichael M; Najarian R; Fu Y; Wang Y; Argani P; Grisanzio C; Signoretti S
Am J Clin Pathol; 2010 Dec; 134(6):873-9. PubMed ID: 21088149
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma.
Phuoc NB; Ehara H; Gotoh T; Nakano M; Kamei S; Deguchi T; Hirose Y
Oncol Rep; 2008 Sep; 20(3):525-30. PubMed ID: 18695901
[TBL] [Abstract][Full Text] [Related]
19. Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.
Zhang BY; Thompson RH; Lohse CM; Dronca RS; Cheville JC; Kwon ED; Leibovich BC
BJU Int; 2013 Jun; 111(7):1046-53. PubMed ID: 23551810
[TBL] [Abstract][Full Text] [Related]
20. Molecular biomarkers for advanced renal cell carcinoma: implications for prognosis and therapy.
Kim HS; Kim WS; Park SH; Jung CW; Choi HY; Lee HM; Jeon SS; Ha H; Hwang IG; Lee S; Lim HY
Urol Oncol; 2010; 28(2):157-63. PubMed ID: 18976937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
